Through its esteemed Board of Directors, Achillion has access to a broad range of business and pharmaceutical development acumen.
Dr. Fisherman is Managing Director of Synthesis Capital, formerly Advent Healthcare Ventures, a life science venture capital firm, where he specializes in biotechnology and emerging pharmaceutical investments. He has served as a director of Achillion since March 2000.
Mr. Frashier joined Achillion's Board of Directors in March 2008. Formerly holding chief executive and/or chairman roles at OSI Pharmaceuticals, Millipore Corporation, Merrimack Pharmaceuticals and eXegenics, Mr. Frashier currently is principal with Management Associates, a life sciences consulting firm.
Mr. Kishbauch currently serves as the President and Chief Executive Officer of Achillion.
Dr. Liotta for over thirty years has been a pharmaceutical researcher, consultant and professor of chemistry at Emory University, Atlanta. He serves on the scientific advisory boards of a number of biopharmaceutical companies. He joined the board of directors of Achillion in December 2008.
Mr. Scheer is President of Scheer & Company, Inc., a firm that provides corporate strategic advisory services, focusing on companies in the life sciences industry. Mr. Scheer has served as a director of Achillion since August 1998 and as Chairman of the Board since March 2010. READ FULL BIO
David Scheer, was involved in the founding of Achillion, and currently serves as its Chairman of the Board. He is President of Scheer & Company, Inc., a firm founded in 1981, with activities in venture capital, corporate strategy, and transactional advisory services focused on the life sciences. Mr. Scheer was involved in the founding and had been a member of the Boards of Directors of ViroPharma, Inc.(NASDAQ, "VPHM"), OraPharma, Inc. (acquired by Johnson & Johnson in 2003), and Esperion Therapeutics, Inc. (of which he was Chairman, acquired by Pfizer in 2004). His other current board relationships include Tengion, Inc. (of which he is Chairman, NASDAQ, "TNGN"), Aegerion Pharmaceuticals, Inc. (of which he is Chairman, NASDAQ, "AEGR"), Optherion, Inc. (of which he is Chairman), and Axerion Therapeutics, Inc. (of which he is Chairman). From 1991 through 1999, he was affiliated with the health care investing team at Oak Investment Partners. Mr. Scheer has also led or played a significant role in a series of transactions involving corporate alliances, licensing arrangements, divestments, acquisitions and mergers in the life sciences. He has served as a member of the Leadership Council of the Harvard School of Public Health, and as a member of the Advisory Committee to the Harvard Malaria Initiative. He has helped to launch, and served as Chair of the Executive Committee for "The Unfinished Agenda in Infectious Diseases", an initiative at the Harvard School of Public Health focusing on the neglected diseases. He has also been a member of the Global Advisory Council for AIDS@30, an initiative at Harvard, and the Chair of the Strategic Advisory Committee for the Global Task Force for Expanding Cancer Care and Control in the Developing World, another Harvard-affiliated initiative. He has also been a member of the Board of Trustees, and most recently Vice-Chair for the Long Wharf Theatre, in New Haven, CT. In 2007, he was awarded the Atlas Award for Venture Capital from the Connecticut Union for Research Excellence (CURE, of which he also serves as a member of the Board), and in 2009, he received the Venture Capital Leadership Award from the Connecticut Venture Group. He received his A.B. cum laude from Harvard College, and an M.S. from Yale University.
Mr. Graves, who joined our Board in June 2012, is Chairman, President and Chief Executive Officer of Intarcia Therapeutics, Inc. Mr. Graves previously held senior management roles at Merck, Novartis and Vertex Pharmaceuticals, and currently serves on the boards of Radius, Pulmatrix and Springleaf.